drugset / Trial / NCT03256422

Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients

NCT03256422 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The trial is an open-label, multicenter, prospective, randomized trial in 2 parallel groups, evaluating at W48, the non-inferiority of antiretroviral treatment taken 4 consecutive days a week versus continuous therapy, in HIV infected patients with controlled viral load for at least 12 months and stable antiretroviral treatment since 4 months.

Timeline

Start
2017-09-07
Primary completion
2019-08-06
Completion
2020-03-02

Drugs

EvaluationDrugModalityDoseRoute
Background Abacavir Other / unclassified — —
Background Atazanavir Other / unclassified — —
Background Darunavir Small molecule — —
Background Dolutegravir Other / unclassified — —
Background Efavirenz Other / unclassified — —
Background Etravirine Small molecule — —
Background Lamivudine Other / unclassified — —
Background Lopinavir Other / unclassified — —
Background Raltegravir Other / unclassified — —
Background Rilpivirine Small molecule — —
Background Tenofovir Small molecule — —
Background elvitegravir/cobicistat Unknown — —
Background emtricitabine Other / unclassified — —